ArticleMolecules (Basel, Switzerland)2022
Design, Synthesis and Preclinical Assessment of
Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06753513 (Clinical Application of 99mTc-FDPH46 SPECT/CT Imaging in Malignant Solid Tumor), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Application of 99mTc-FDPH46 SPECT/CT Imaging in Malignant Solid Tumor: a Prospective Exploratory Study
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- Single Photon Emission Computed Tomography Tracer.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- Fibroblast activation protein targeting radiopharmaceuticals: From drug design to clinical translation.Acta pharmaceutica Sinica. B · 2025Review
- New horizons in nuclear cardiology: Imaging of peripheral arterial disease.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2025Review
- Imaging Fibroblast Activation Protein: Direct Visualization of Matrix Proteolytic Activity in Patients Post Myocardial Infarction.Journal of the American College of Cardiology · 2025Article
- Monovalent and Divalent Designs of Copper Radiotheranostics Targeting Fibroblast Activation Protein in Cancer.Cancers · 2024Article
- Review
- FAP-Targeted Nanoparticle-based Imaging in Cancer: A Systematic Review.Journal of biomedical physics & engineering · 2024Review
- Review
- Article
- Beyond Small Molecules: Antibodies and Peptides for Fibroblast Activation Protein Targeting Radiopharmaceuticals.Pharmaceutics · 2024Review
- Article
- Design, Synthesis, and Evaluation ofACS pharmacology & translational science · 2023Article
- Theranostics in targeting fibroblast activation protein bearing cells: Progress and challenges.Life sciences · 2023Review
- Synthesis and Evaluation ofInternational journal of molecular sciences · 2023Article
- Synthesis and Preclinical Evaluation of NovelPharmaceuticals (Basel, Switzerland) · 2023Article
- NovelPharmaceuticals (Basel, Switzerland) · 2023Article
- A novel molecular imaging probe [Scientific reports · 2023Article
- Toxicity Assessment of [Nanomaterials (Basel, Switzerland) · 2022Article
- [Pharmaceuticals (Basel, Switzerland) · 2022Article
- [Pharmaceuticals (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
Abstract
Fibroblast activation protein (FAP) is expressed in the microenvironment of most human epithelial tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.